Seom guidelines for the treatment of gastric cancer 2015

被引：0
作者：
M. Martin-Richard
A. Custodio
C. García-Girón
C. Grávalos
C. Gomez
P. Jimenez-Fonseca
J. L. Manzano
C. Pericay
F. Rivera
A. Carrato
机构：
[1] Hospital de la Santa Creu I Sant Pau,Medical Oncology Department
[2] Hospital Universitario Clínico San Carlos,Medical Oncology Department
[3] Hospital Universitario de Burgos,Medical Oncology Department
[4] Hospital Universitario 12 de Octubre,Medical Oncology Department
[5] Hospital Universitario Central de Asturias (HUCA),Medical Oncology Department
[6] Hospital Universitari Germans Trias I Pujol de Badalona,Medical Oncology Department
[7] Hospital de Sabadell-Consorcio Sanitario Parc Taulì,Medical Oncology Department
[8] Hospital Universitario Marqués de Valdecilla,Medical Oncology Department
[9] Hospital Universitario Ramón y Cajal,Medical Oncology Department
来源：
Clinical and Translational Oncology | 2015年 / 17卷
关键词：
Gastric adenocarcinoma; Cardia; Diagnosis; Treatment; Clinical guidelines;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Gastric cancer is the fourth cause of death by cancer in Spain and a significant medical problem. Molecular biology results evidence that gastroesophageal junction tumors and gastric cancer should be considered as two independent entities with a different prognosis and treatment approach. Endoscopic resection in very early tumors is feasible. Neoadjuvant and adjuvant therapy in locally advanced resectable tumor increase overall survival and should be considered standard treatments. In stage IV tumors, platinum–fluoropyrimidine-based schedule, with trastuzumab in HER2-overexpressed tumors, is the first-line treatment. Different therapies in second line have demonstrated in randomized studies their clear benefit in survival improvement.
引用
收藏
页码：996 / 1004
页数：8
相关论文
共 286 条
  • [21] Klimstra DS(2014)Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria Gastric Cancer 97 868-1069
  • [22] Gerdes H(2010)Treatment modalities for early gastric cancer Br J Surg 7 1062-449
  • [23] Lei Z(2015)Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial World J Gastrointest Endosc. 11 439-814
  • [24] Tan IB(2010)Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis Lancet Oncol. 107 807-5218
  • [25] Das K(2013)Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954 J Surg Oncol 28 5210-692
  • [26] Deng N(2010)Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis J Clin Oncol 12 681-856
  • [27] Zouridis H(2011)Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction Lancet Oncol. 27 851-1098
  • [28] Pattison S(2009)Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial J Clin Oncol 16 1090-20
  • [29] Deng N(2015)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer Lancet Oncol. 355 11-1721
  • [30] Goh LK(2006)Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial N Engl J Med 29 1715-3158
12345678910